Luye Pharma Group Ltd. (02186.HK) Latest Company News

Oct 16, 2026, 07:50 UTC
Luye Pharma Group Ltd. appointed Liu Fei and Yin Chengqiang as deputy general managers, with terms lasting until the end of the 12th board's term.
Source:
- finance.sina.cn
Sep 21, 2026, 05:59 UTC
Luye Pharma's ERZOFRI received U.S. approval and is being commercially launched by the company's own U.S. commercialization team.
Source:
- tmtpost.com
Sep 21, 2026, 02:51 UTC
Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.
Source:
- aastocks.com
Sep 1, 2026, 09:11 UTC
Shandong Commercial Group transferred 5% of Furuida's shares to Shandong State-owned Assets Investment Holding Co., Ltd., completing registration on August 31, 2026.
Source:
- finance.sina.cn
Aug 30, 2026, 18:50 UTC
Luye Pharma Group announced its interim results for the six months ended June 2026, with net profit of RMB 390 million, up 24.8% year-on-year, and revenue of RMB 3.002 billion, down 5.6%.
Source:
- aastocks.com
Aug 20, 2026, 14:38 UTC
Luye Pharma announced that its self-developed mRNA vaccine LY01620 will soon enter Phase II clinical trials in China for HPV16-positive high-grade cervical squamous intraepithelial lesions.
Source:
Aug 5, 2026, 13:48 UTC
Luye Pharma Group announced that its self-developed new molecular entity LY03015 has completed a bridging clinical trial in the United States, supporting its upcoming efficacy clinical trial in the United States.
Source:
- finance.sina.cn
- aastocks.com

02186.HK

Luye Pharma Group Ltd. appointed Liu Fei and Yin Chengqiang as deputy general managers, with terms lasting until the end of the 12th board's term.

Luye Pharma's ERZOFRI received U.S. approval and is being commercially launched by the company's own U.S. commercialization team.

Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.

Shandong Commercial Group transferred 5% of Furuida's shares to Shandong State-owned Assets Investment Holding Co., Ltd., completing registration on August 31, 2026.

Luye Pharma Group announced its interim results for the six months ended June 2026, with net profit of RMB 390 million, up 24.8% year-on-year, and revenue of RMB 3.002 billion, down 5.6%.

Luye Pharma announced that its self-developed mRNA vaccine LY01620 will soon enter Phase II clinical trials in China for HPV16-positive high-grade cervical squamous intraepithelial lesions.

Luye Pharma Group announced that its self-developed new molecular entity LY03015 has completed a bridging clinical trial in the United States, supporting its upcoming efficacy clinical trial in the United States.